Acute Bacterial Skin & Skin Structure Infection Market by Infection Type (Community-Acquired ABSSI, Hospital Acquired ABSSI), Disease Category (Nonpurulent, Purulent), Route of Administration, Distribution Channel - Global Forecast 2024-2030

Acute Bacterial Skin & Skin Structure Infection Market by Infection Type (Community-Acquired ABSSI, Hospital Acquired ABSSI), Disease Category (Nonpurulent, Purulent), Route of Administration, Distribution Channel - Global Forecast 2024-2030


The Acute Bacterial Skin & Skin Structure Infection Market size was estimated at USD 10.52 billion in 2023 and expected to reach USD 11.35 billion in 2024, at a CAGR 8.63% to reach USD 18.79 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acute Bacterial Skin & Skin Structure Infection Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acute Bacterial Skin & Skin Structure Infection Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acute Bacterial Skin & Skin Structure Infection Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Accord Healthcare Limited, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Basilea Pharmaceutica Ltd, BiVictriX Therapeutics PLC, Cadila Pharmaceuticals Limited, Cumberland Pharmaceuticals Inc., Debiopharm SA, Destiny Pharma PLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Innovation Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., KBP Biosciences Co., Ltd., Melinta Therapeutics, LLC, Merck & Co, Inc, MicuRx Pharmaceuticals, Inc., Novartis International AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Bacterial Skin & Skin Structure Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

Infection Type

Community-Acquired ABSSI
  • Hospital Acquired ABSSI
  • Disease Category

    Nonpurulent
  • Purulent
  • Route of Administration

    Oral
  • Parenteral
  • Topical
  • Distribution Channel

    Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Acute Bacterial Skin & Skin Structure Infection Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acute Bacterial Skin & Skin Structure Infection Market?
    3. What are the technology trends and regulatory frameworks in the Acute Bacterial Skin & Skin Structure Infection Market?
    4. What is the market share of the leading vendors in the Acute Bacterial Skin & Skin Structure Infection Market?
    5. Which modes and strategic moves are suitable for entering the Acute Bacterial Skin & Skin Structure Infection Market?


    Note: PDF & Excel + Online Access - 1 Year

  • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Acute Bacterial Skin & Skin Structure Infection Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rising prevalence and cases of bacterial skin infections
    5.1.1.2. Increasing people awareness about skin problems
    5.1.1.3. Growth in number of dermatology centers and clinics
    5.1.2. Restraints
    5.1.2.1. Associated adverse health impacts of ABSSSI drugs
    5.1.3. Opportunities
    5.1.3.1. Ongoing R&D activities for development of novel drugs
    5.1.3.2. Surge in regulatory approvals from clinical authorities
    5.1.4. Challenges
    5.1.4.1. Lack of standard protocols and mismanaged treatments
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type
    6.1. Introduction
    6.2. Community-Acquired ABSSI
    6.3. Hospital Acquired ABSSI
    7. Acute Bacterial Skin & Skin Structure Infection Market, by Disease Category
    7.1. Introduction
    7.2. Nonpurulent
    7.3. Purulent
    8. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration
    8.1. Introduction
    8.2. Oral
    8.3. Parenteral
    8.4. Topical
    9. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel
    9.1. Introduction
    9.2. Hospital Pharmacies
    9.3. Online Pharmacies
    9.4. Retail Pharmacies
    10. Americas Acute Bacterial Skin & Skin Structure Infection Market
    10.1. Introduction
    10.2. Argentina
    10.3. Brazil
    10.4. Canada
    10.5. Mexico
    10.6. United States
    11. Asia-Pacific Acute Bacterial Skin & Skin Structure Infection Market
    11.1. Introduction
    11.2. Australia
    11.3. China
    11.4. India
    11.5. Indonesia
    11.6. Japan
    11.7. Malaysia
    11.8. Philippines
    11.9. Singapore
    11.10. South Korea
    11.11. Taiwan
    11.12. Thailand
    11.13. Vietnam
    12. Europe, Middle East & Africa Acute Bacterial Skin & Skin Structure Infection Market
    12.1. Introduction
    12.2. Denmark
    12.3. Egypt
    12.4. Finland
    12.5. France
    12.6. Germany
    12.7. Israel
    12.8. Italy
    12.9. Netherlands
    12.10. Nigeria
    12.11. Norway
    12.12. Poland
    12.13. Qatar
    12.14. Russia
    12.15. Saudi Arabia
    12.16. South Africa
    12.17. Spain
    12.18. Sweden
    12.19. Switzerland
    12.20. Turkey
    12.21. United Arab Emirates
    12.22. United Kingdom
    13. Competitive Landscape
    13.1. FPNV Positioning Matrix
    13.2. Market Share Analysis, By Key Player
    13.3. Competitive Scenario Analysis, By Key Player
    14. Competitive Portfolio
    14.1. Key Company Profiles
    14.1.1. Abbvie, Inc.
    14.1.2. Accord Healthcare Limited
    14.1.3. Amneal Pharmaceuticals, Inc.
    14.1.4. Aurobindo Pharma Limited
    14.1.5. Basilea Pharmaceutica Ltd
    14.1.6. BiVictriX Therapeutics PLC
    14.1.7. Cadila Pharmaceuticals Limited
    14.1.8. Cumberland Pharmaceuticals Inc.
    14.1.9. Debiopharm SA
    14.1.10. Destiny Pharma PLC
    14.1.11. Fresenius SE & Co. KGaA
    14.1.12. GlaxoSmithKline PLC
    14.1.13. Glenmark Pharmaceuticals Limited
    14.1.14. Innovation Pharmaceuticals Inc.
    14.1.15. Intas Pharmaceuticals Ltd.
    14.1.16. KBP Biosciences Co., Ltd.
    14.1.17. Melinta Therapeutics, LLC
    14.1.18. Merck & Co, Inc
    14.1.19. MicuRx Pharmaceuticals, Inc.
    14.1.20. Novartis International AG
    14.1.21. Paratek Pharmaceuticals, Inc.
    14.1.22. Pfizer Inc.
    14.1.23. Sun Pharmaceutical Industries Limited
    14.1.24. Teva Pharmaceutical Industries Ltd.
    14.2. Key Product Portfolio
    15. Appendix
    15.1. Discussion Guide
    15.2. License & Pricing
    FIGURE 1. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET RESEARCH PROCESS
    FIGURE 2. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2023 VS 2030
    FIGURE 3. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET DYNAMICS
    FIGURE 7. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
    FIGURE 8. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2030 (%)
    FIGURE 10. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISEASE CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 12. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
    FIGURE 14. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 18. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 24. ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2023

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings